Drugs / Polypodium Leucotomos
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00520910 | Aug 2007 → May 2009 | skin disorder | University of Miami | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02904798 | Jul 2015 → Feb 2017 | photosensitivity disease | Henry Ford Health System | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polypodium Leucotomos | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02904798 ↗ |
| Route | Oral | “7.5 mg/kg oral dose of Polypodium leucotomos” NCT00520910 ↗ |